Dopamine receptor type 2 (<scp>DRD2</scp>) and somatostatin receptor type 2 (<scp>SSTR2</scp>) agonists are effective in inhibiting proliferation of progenitor/stem‐like cells isolated from nonfunctioning pituitary tumors
Erika Peverelli(University of Milan), Giovanna Mantovani(University of Milan)
Cited by 60
Related Papers
Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells
|Neuroendocrinology|2019|19
The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells
|Cancer Letters|2020|17
A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation
|Frontiers in Endocrinology|2021|14
TMPRSS2 Expression and Activity Modulation by Sex-Related Hormones in Lung Calu-3 Cells: Impact on Gender-Specific SARS-CoV-2 Infection
|Frontiers in Endocrinology|2022|8
Therapeutic potential of targeting the FLNA‐regulated Wee1 kinase in adrenocortical carcinomas
|International Journal of Cancer|2024|6